This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bear of the Day: Elevance Health (ELV)
by Derek Lewis
A big guidance cut paints a challenging picture for the company's shares in the near term.
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
by Zacks Equity Research
CI's Q2 results are likely to hinge on Evernorth's growth as core healthcare revenues and premiums face steep declines.
Can Humana Beat Q2 Earnings Estimates on Insurance Unit Strength?
by Zacks Equity Research
HUM's second-quarter earnings are likely to have witnessed strength in insurance premiums and Medicare, partly offset by rising costs and membership declines.
Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?
by Zacks Equity Research
UNH leans on Optum's diversified growth and value-based care to counter insurance sector margin pressure in Q2.
Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss
by Zacks Equity Research
CNC reports rare Q2 loss amid surging medical costs, lower investment and other income despite strong revenue growth.
Company News for Jul 18, 2025
by Zacks Equity Research
Companies in The News Are: CTAS,CFG,TRV,ELV
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
by Moumi Mondal
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
Elevance Health Q2 Earnings Miss Estimates on Rising Medical Costs
by Zacks Equity Research
ELV's Q2 EPS slides 12.6% y/y and misses estimates as rising Medicaid and ACA costs weigh on the results.
Elevance Health (ELV) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?
by Zacks Equity Research
ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.
Elevance Health (ELV) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Elevance Health (ELV), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Earnings Preview: Elevance Health (ELV) Q2 Earnings Expected to Decline
by Zacks Equity Research
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth Dropped From Russell Growth: How to Trade UNH Now
by Kaibalya Pravo Dey
UNH's removal from key Russell growth indices caps a turbulent stretch marked by steep losses, rising costs and regulatory woes.
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Will CVS Health's Formulary Move Boost Its Weight Management Program?
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Is AI the Key to UnitedHealth's Market Growth and Cost Control?
by Kaibalya Pravo Dey
UNH ramps up AI use to cut costs, boost efficiency, and reshape healthcare workflows, but legal risks remain.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Can Optum Offset UnitedHealth's Health Benefits Growth Woes?
by Zacks Equity Research
Optum drives growth for UNH as rising Medicare Advantage costs pressure its health benefits unit.
CVS Health's MBR Improves: Can It Sustain Amid Elevated Cost Trends?
by Moumi Mondal
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.
UnitedHealth's Medical Membership Rises: Can It Maintain the Momentum?
by Zacks Equity Research
UNH's medical membership tops 50M amid rising demand. However, high Medicare costs cloud its growth outlook.
UnitedHealth to Curtail Medicare Advantage Costs: Margin Boost Ahead?
by Zacks Equity Research
UNH's CEO pledges reform after rare earnings miss as rising Medicare Advantage costs squeeze margins and spook investors.
UnitedHealth Declines 40.4% YTD: Here's Why it's Still Not a Bargain
by Kaibalya Pravo Dey
UNH shares have plunged YTD, but regulatory risks, cost pressures and earnings downgrades keep it far from a bargain.
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
by Kaibalya Pravo Dey
Strong capital efficiency and commercial growth make ELV appealing, but regulatory and cost headwinds keep investors cautious.
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
by Kaibalya Pravo Dey
ELV outpaces UNH with stronger earnings, leaner costs and clearer guidance, making it the healthcare stock with more upside right now.